Antibiotic Adjuvants: Rescuing Antibiotics from Resistance

Trends in Microbiology

Volumn 24, Issue 11, 2016, Pages 862-871

  Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

antibacterial; drug combinations; drug discovery; inhibitor

Indexed keywords

ADJUVANT; ANTIBIOTIC AGENT; AVIBACTAM; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTOLOZANE PLUS TAZOBACTAM; CLAVULANIC ACID; LOPERAMIDE; STREPTAZOLIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BIOFILM; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; IMMUNOMODULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; BACTERIAL INFECTION; BACTERIUM; CHEMISTRY; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG POTENTIATION; MULTIDRUG RESISTANCE; PHYSIOLOGY;

ADJUVANTS, PHARMACEUTIC; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; DRUG COMBINATIONS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS;

EID: 84994518759     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2016.06.009     Document Type: Review

References (57)

1. 1 WHO, Antibiotic Resistance: Multi-Country Public Awareness Survey. 2015, 51.
2. 2 Taneja, N., Kaur, H., Insights into newer antimicrobial agents against gram-negative bacteria. Microbiol. Insights 9 (2016), 9–19.
3. 3 Rex, J.H., Outterson, K., Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect. Dis. 16 (2016), 500–505.
4. 4 Payne, D.J., et al. Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos. Trans. R. Soc. Lond. B Biol. Sci., 370, 2015, 20140086.
5. 5 Rex, J.H., et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect. Dis. 13 (2013), 269–275.
6. 6 Wright, G.D., Solving the Antibiotic Crisis. ACS Infect. Dis. 1 (2015), 80–84.
7. 7 Brown, D.G., et al. Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. J. Med. Chem. 57 (2014), 10144–10161.
8. 8 Zgurskaya, H.I., et al. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect. Dis. 1 (2015), 512–522.
9. 9 Payne, D.J., et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug. Discov. 6 (2007), 29–40.
10. 10 Tommasi, R., et al. ESKAPEing the labyrinth of antibacterial discovery. Nat. Rev. Drug. Discov. 14 (2015), 529–542.
11. 11 Brown, E.D., Wright, G.D., Antibacterial drug discovery in the resistance era. Nature 529 (2016), 336–343.
12. 12 Laxminarayan, R., et al. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 13 (2013), 1057–1098.
13. 13 Zumla, A., et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections–needs, advances, and future prospects. Lancet Infect. Dis. 14 (2014), 1123–1135.
14. 14 Bernal, P., et al. Antibiotic adjuvants: identification and clinical use. Microb. Biotechnol. 6 (2013), 445–449.
15. 15 Gill, E.E., et al. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem. Biol. Drug Des. 85 (2015), 56–78.
16. 16 Kalan, L., Wright, G.D., Antibiotic adjuvants: multicomponent anti-infective strategies. Expert. Rev. Mol. Med., 13, 2011, e5.
17. 17 Drusano, G.L., et al. Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, Part 2. Antimicrob. Agents Chemother. 60 (2015), 1194–1201.
18. 18 Worthington, R.J., Melander, C., Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 31 (2013), 177–184.
19. 19 Eliopoulos, G.M., Eliopoulos, C.T., Antibiotic combinations: should they be tested?. Clin. Microbiol. Rev. 1 (1988), 139–156.
20. 20 Mann, P.A., et al. Murgocil is a highly bioactive staphylococcal-specific inhibitor of the peptidoglycan glycosyltransferase enzyme MurG. ACS Chem. Biol. 8 (2013), 2442–2451.
21. 21 Wildenhain, J., et al. Prediction of synergism from chemical-genetic interactions by machine learning. Cell Syst. 1 (2015), 383–395.
22. 22 Brown, D., Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?. Nat. Rev. Drug Discov. 14 (2015), 821–832.
23. 23 Reading, C., Cole, M., Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 11 (1977), 852–857.
24. 24 Neu, H.C., Fu, K.P., Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob. Agents Chemother. 14 (1978), 650–655.
25. 25 Bush, K., A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int. J. Antimicrob. Agents 46 (2015), 483–493.
26. 26 Shlaes, D.M., New beta-lactam-beta-lactamase inhibitor combinations in clinical development. Ann. N. Y. Acad. Sci. 1277 (2013), 105–114.
27. 27 Dortet, L., et al. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed. Res. Int., 2014, 2014, 249856.
28. 28 King, A.M., et al. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510 (2014), 503–506.
29. 29 Becker, B., Cooper, M.A., Aminoglycoside antibiotics in the 21st century. ACS Chem. Biol. 8 (2013), 105–115.
30. 30 Shakya, T., et al. A small molecule discrimination map of the antibiotic resistance kinome. Chem. Biol. 18 (2011), 1591–1601.
31. 31 Stogios, P.J., et al. Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance. Biochem. J. 454 (2013), 191–200.
32. 32 Allen, N.E., et al. 7-Hydroxytropolone: an inhibitor of aminoglycoside-2“-O-adenylyltransferase. Antimicrob. Agents Chemother. 22 (1982), 824–831.
33. 33 Hirsch, D.R., et al. Inhibition of the ANT(2”)-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic alpha-hydroxytropolones. Bioorg. Med. Chem. Lett. 24 (2014), 4943–4947.
34. 34 Boehr, D.D., et al. Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chem. Biol. 10 (2003), 189–196.
35. 35 Ejim, L., et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7 (2011), 348–350.
36. 36 Farha, M.A., et al. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem. Biol. 20 (2013), 1168–1178.
37. 37 Farha, M.A., et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to beta-lactams. ACS Chem. Biol. 8 (2013), 226–233.
38. 38 Lee, S.H., et al. TarO-specific inhibitors of wall teichoic acid biosynthesis restore beta-lactam efficacy against methicillin-resistant staphylococci. Sci. Transl. Med., 8, 2016, 329ra332.
39. 39 Wang, H., et al. Discovery of wall teichoic acid inhibitors as potential anti-MRSA beta-lactam combination agents. Chem. Biol. 20 (2013), 272–284.
40. 40 Taylor, P.L., et al. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 7 (2012), 1547–1555.
41. 41 Cox, G., et al. An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria. J. Antimicrob. Chemother. 69 (2014), 1844–1855.
42. 42 Worthington, R.J., et al. Small molecule suppression of carbapenem resistance in NDM-1 producing Klebsiella pneumoniae. ACS Med. Chem. Lett. 3 (2012), 357–361.
43. 43 Harris, T.L., et al. Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus. Angew Chem. Int. Ed. Engl. 51 (2012), 11254–11257.
44. 44 Brackett, C.M., et al. Small-molecule suppression of beta-lactam resistance in multidrug-resistant gram-negative pathogens. J. Med. Chem. 57 (2014), 7450–7458.
45. 45 Li, X.Z., et al. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28 (2015), 337–418.
46. 46 Lomovskaya, O., et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45 (2001), 105–116.
47. 47 Nguyen, U.T., et al. Small-molecule modulators of Listeria monocytogenes biofilm development. Appl. Environ. Microbiol. 78 (2012), 1454–1465.
48. 48 Wenderska, I.B., et al. Palmitoyl-DL-carnitine is a multitarget inhibitor of Pseudomonas aeruginosa biofilm development. Chembiochem. 12 (2011), 2759–2766.
49. 49 Reffuveille, F., et al. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob. Agents Chemother. 58 (2014), 5363–5371.
50. 50 Brackman, G., et al. The quorum sensing inhibitor hamamelitannin increases antibiotic susceptibility of Staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA release. Sci. Rep., 6, 2016, 20321.
51. 51 Rabin, N., et al. Agents that inhibit bacterial biofilm formation. Future Med. Chem. 7 (2015), 647–671.
52. 52 Ribeiro, S.M., et al. New frontiers for anti-biofilm drug development. Pharmacol. Ther. 160 (2016), 133–144.
53. 53 Liu, A., et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob. Agents Chemother. 54 (2010), 1393–1403.
54. 54 French, S., et al. A robust platform for chemical genomics in bacterial systems. Mol. Biol. Cell 27 (2016), 1015–1025.
55. 55 Hancock, R.E., et al. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 10 (2012), 243–254.
56. 56 Cassone, M., Otvos, L. Jr., Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev. Anti. Infect. Ther. 8 (2010), 703–716.
57. 57 Perry, J.A., et al. A macrophage-stimulating compound from a screen of microbial natural products. J. Antibiot. (Tokyo) 68 (2015), 40–46.